MedTrace Logo

Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy

NCT03221075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2023-05-12

No results posted yet for this study

Summary

In order to determine the efficacy of antifungal therapy in patients with documented azole-resistant invasive Aspergillosis (IA), anonymized clinical information of patients with a hematological malignancy with a culture-positive invasive fungal infection caused by Aspergillus fumigatus are collected in an online registry. Respective fungal isolates are analysed for azole susceptibility and resistance mechanisms. Patients diagnosed with an IA in 2016 and later are included in the study.

Conditions

  • Invasive Aspergillosis

Interventions

OTHER

Registry

There is no intervention.

Sponsors & Collaborators

  • Radboud University Medical Center

    collaborator OTHER

  • University Hospital of Cologne

    lead OTHER

Principal Investigators

  • Oliver A. Cornely, Prof. · University Hospital of Cologne, Germany

  • Paul E. Verweij, Prof. · Radboud University Nijmegen Medical Center, The Netherlands

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2022-04-30
Completion
2022-10-25

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03221075 on ClinicalTrials.gov